期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (1)
Although reactive large granular lymphocytosis due to diverse etiologies is not an uncommon finding in clinical practice, isolated natural killer (NK)......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (4)
Telomere dysfunctions are associated with several hematopoietic stem cell (HSC) malignancies. Recent findings have indicated that the occurrence of ra......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (3)
Understanding the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is needed to identify patients who......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (5)
Low socioeconomic position (SEP) may be associated with adverse outcomes in patients with myelodysplastic syndromes (MDS) inherent to for example, del......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (4)
The introduction of Bruton's tyrosine kinase (BTK) inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the f......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (4)
It has been established that Cutaneous T-Cell lymphomas (CTCL) are caused by the monoclonal proliferation of T lymphocytes in the skin. This heterogen......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (3)
In symptomatic Waldenstrom macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In folli......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (5)
Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several m......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (1)
Acute Lymphocytic Leukemia (ALL) is a malignancy that originates from immature lymphoid cells and is clinically established with flow cytometry throug......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (4)
Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T-cell therapy (CART) are salvage therapies that are utilised ......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (4)
Treatment for relapsed/refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) is evolving rapidly due to the emergence of novel drugs, of which histone ......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (1)
The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantatio......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (2)
To evaluate the outcome and prognostic significance of CEBPA mutations among pediatric acute myeloid leukemia (AML) from TARGET dataset. A total of 18......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (2)
Exosomal microRNAs (miRNAs) are potential biomarkers for a variety of tumors, but have not yet been studied in diffuse large B-cell lymphoma (DLBCL). ......
期刊： HEMATOLOGICAL ONCOLOGY, 2022; 40 (2)
Lymphomas of the nasal cavity and paranasal sinuses (NPS) are rare. Knowledge on sinonasal B-cell lymphoma (SNBCL) primarily comes from case series or......
